Physician profile
Joshua Rudd
NPI 1609030063
$1,963.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $16.32 · 2021: $104 · 2022: $78.61 · 2023: $128 · 2024: $30.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $1,423.00 | 2019-2023 | Phasix Mesh |
| C. R. Bard, INC. & Subsidiaries | $150.16 | 2019 | |
| Medtronic, INC. | $70.45 | 2021-2023 | Closurefast |
| Smith+Nephew, INC. | $49.91 | 2023 | Stravix, Grafix Pl |
| Biocompatibles, INC. | $47.67 | 2019 | |
| Organogenesis INC. | $45.15 | 2023 | Puraply |
| Bard Peripheral Vascular, INC. | $42.65 | 2021 | |
| Merit Medical Systems INC | $30.40 | 2024 | Savi Scout |
| Innocoll Pharmaceuticals Limited | $26.55 | 2022 | |
| Stryker Corporation | $17.64 | 2021 | |
| Focal Therapeutics, INC. | $16.66 | 2019 | |
| Kci USA, INC. | $16.32 | 2020 | |
| Tela Bio, INC. | $15.74 | 2022 | |
| Olympus America INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Rudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.